EyePoint Pharmaceuticals, Inc. (FRA:PV3B)
12.24
-0.27 (-2.16%)
Last updated: Dec 1, 2025, 9:15 AM CET
EyePoint Pharmaceuticals Employees
EyePoint Pharmaceuticals had 165 employees as of December 31, 2024. The number of employees increased by 44 or 36.36% compared to the previous year.
Employees
165
Change (1Y)
44
Growth (1Y)
36.36%
Revenue / Employee
€218,700
Profits / Employee
€1,062,803
Market Cap
1.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 165 | 44 | 36.36% |
| Dec 31, 2023 | 121 | -23 | -15.97% |
| Dec 31, 2022 | 144 | 21 | 17.07% |
| Dec 31, 2021 | 123 | 22 | 21.78% |
| Dec 31, 2020 | 101 | 17 | 20.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
EyePoint Pharmaceuticals News
- 12 days ago - EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DURAVYU Trials - GuruFocus
- 12 days ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration - Wallstreet:Online
- 12 days ago - EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - GlobeNewsWire
- 14 days ago - EyePoint (EYPT) Grants Stock Options to New Employees - GuruFocus
- 14 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Insider Sell: Ramiro Ribeiro Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) - GuruFocus
- 24 days ago - EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - GuruFocus
- 24 days ago - Q3 2025 EyePoint Pharmaceuticals Inc Earnings Call Transcript - GuruFocus